top of page

Browse by category

Search

Tonix to initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900

Tonix to initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900

Tonix to initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900

Tonix Pharmaceuticals plans to progress its TNX-2900 programme for the treatment of Prader-Willi syndrome (PWS) into a Phase 2 clinical...

FDA approves Tonix’ Phase 2 Trial of TNX-2900 for Prader-Willi Syndrome

FDA approves Tonix’ Phase 2 Trial of TNX-2900 for Prader-Willi Syndrome

FDA approves Tonix’ Phase 2 Trial of TNX-2900 for Prader-Willi Syndrome

The FDA has cleared Tonix Pharmaceuticals’ Investigational New Drug (IND) application to support clinical development of TNX-2900...

OMMs appear to be valid alternatives to EBP and MBS for mild-to-moderate obesity, but surgery more effective for patients with a higher degree of obesity

12 hours ago

MyPhenome test predicts GLP-1 response and obesity risk in large, diverse populations

13 hours ago

Apnimed’s sulthiame's demonstrates efficacy in obstructive sleep apnoea

2 days ago

Back to Top

bottom of page